|
[1]
|
Rinella, M.E., Lazarus, J.V., Ratziu, V., et al. (2023) A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. Journal of Hepatology, 79, 1542-1556. [Google Scholar] [CrossRef]
|
|
[2]
|
Hagström, H., Vessby, J., Ekstedt, M., et al. (2024) 99% of Patients with NAFLD Meet MASLD Criteria and Natural History Is Therefore Identical. Journal of Hepatology, 80, E76-E77. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Lee, H., Lee, Y.H., Kim, S.U., et al. (2021) Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clinical Gastroenterology and Hepatology, 19, 2138-2147.E2110. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Sung, K.C., Yoo, T.K., Lee, M.Y., et al. (2023) Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease with Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, 482-491. [Google Scholar] [CrossRef]
|
|
[5]
|
Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., et al. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Riazi, K., Azhari, H., Charette, J.H., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 7, 851-861. [Google Scholar] [CrossRef]
|
|
[7]
|
Schattenberg, J.M., Lazarus, J.V., Newsome, P.N., et al. (2021) Disease Burden and Economic Impact of Diagnosed Non-Alcoholic Steatohepatitis in Five European Countries in 2018: A Cost-of-Illness Analysis. Liver International, 41, 1227-1242. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Long, M.T., Zhang, X., Xu, H., et al. (2021) Hepatic Fibrosis Associates with Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology, 73, 548-559. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Zhou, X.D., Cai, J., Targher, G., et al. (2022) Metabolic Dysfunction-Associated Fatty Liver Disease and Implications for Cardiovascular Risk and Disease Prevention. Cardiovascular Diabetology, 21, Article No. 270. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Simon, T.G., Roelstraete, B., Hagström, H., et al. (2022) Non-Alcoholic Fatty Liver Disease and Incident Major Adverse Cardiovascular Events: Results from a Nationwide Histology Cohort. Gut, 71, 1867-1875. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Byrne, C.D. and Targher, G. (2022) Non-Alcoholic Fatty Liver Disease-Related Risk of Cardiovascular Disease and Other Cardiac Complications. Diabetes, Obesity & Metabolism, 24, 28-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Targher, G., Byrne, C.D. and Tilg, H. (2020) NAFLD and Increased Risk of Cardiovascular Disease: Clinical Associations, Pathophysiological Mechanisms and Pharmacological Implications. Gut, 69, 1691-1705. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Mantovani, A., Petracca, G., Csermely, A., et al. (2022) Non-Alcoholic Fatty Liver Disease and Risk of New-Onset Heart Failure: An Updated Meta-Analysis of about 11 Million Individuals. Gut, 72, 372-380. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chen, Z., Liu, J., Zhou, F., et al. (2021) Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circulation Research, 128, 1747-1765. [Google Scholar] [CrossRef]
|
|
[15]
|
Mantovani, A., Csermely, A., Petracca, G., et al. (2021) Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 6, 903-913. [Google Scholar] [CrossRef]
|
|
[16]
|
Zhou, J., Zhou, F., Wang, W., et al. (2020) Epidemiological Features of NAFLD from 1999 to 2018 in China. Hepatology, 71, 1851-1864. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Stefan, N., Lonardo, A. and Targher, G. (2023) Role of Steatotic Liver Disease in Prediction and Prevention of Cardiometabolic Diseases. Nature Reviews: Gastroenterology & Hepatology, 21, 136-137. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Stahl, E.P., Dhindsa, D.S., Lee, S.K., et al. (2019) Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73, 948-963. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Tilg, H. and Moschen, A.R. (2010) Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology, 52, 1836-1846. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Tosello-Trampont, A.C., Landes, S.G., Nguyen, V., et al. (2012) Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-Induced Mouse Model through Tumor Necrosis Factor-α Production. Journal of Biological Chemistry, 287, 40161-40172. [Google Scholar] [CrossRef]
|
|
[21]
|
Itier, R., Guillaume, M., Ricci, J.E., et al. (2021) Non-Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical Issues. ESC Heart Failure, 8, 789-798. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Cai, J., Zhang, X.J., Ji, Y.X., et al. (2020) Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circulation Research, 126, 679-704. [Google Scholar] [CrossRef]
|
|
[23]
|
Cai, J., Xu, M., Zhang, X., et al. (2019) Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Annual Review of Pathology, 14, 153-184. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Cai, J., Zhang, X.J. and Li, H. (2019) The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. Hepatology, 70, 1026-1037. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Takimoto, E. and Kass, D.A. (2007) Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling. Hypertension, 49, 241-248. [Google Scholar] [CrossRef]
|
|
[26]
|
Sirker, A., Zhang, M., Murdoch, C., et al. (2007) Involvement of NADPH Oxidases in Cardiac Remodelling and Heart Failure. American Journal of Nephrology, 27, 649-660. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Pejnovic, N., Jeftic, I., Jovicic, N., et al. (2016) Galectin-3 and IL-33/ST2 Axis Roles and Interplay in Diet-Induced Steatohepatitis. World Journal of Gastroenterology, 22, 9706-9717. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Wettersten, N. and Maisel, A.S. (2016) Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. American Journal of Medicine, 129, 560-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Wolf, D. and Ley, K. (2019) Immunity and Inflammation in Atherosclerosis. Circulation Research, 124, 315-327. [Google Scholar] [CrossRef]
|
|
[30]
|
Widjaja, A.A., Singh, B.K., Adami, E., et al. (2019) Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis. Gastroenterology, 157, 777-792.E714. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Ridker, P.M., Everett, B.M., Thuren, T., et al. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377, 1119-1131. [Google Scholar] [CrossRef]
|
|
[32]
|
Bhatti, J.S., Bhatti, G.K. and Reddy, P.H. (2017) Mitochondrial Dysfunction and Oxidative Stress in Metabolic Disorders—A Step towards Mitochondria Based Therapeutic Strategies. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1863, 1066-1077. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Betteridge, D.J. (2000) What Is Oxidative Stress? Metabolism: Clinical and Experimental, 49, 3-8. [Google Scholar] [CrossRef]
|
|
[34]
|
Salete-Granado, D., Carbonell, C., Puertas-Miranda, D., et al. (2023) Autophagy, Oxidative Stress, and Alcoholic Liver Disease: A Systematic Review and Potential Clinical Applications. Antioxidants (Basel), 12, Article No. 1425. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Barrea, L., Verde, L., Savastano, S., et al. (2023) Adherence to Mediterranean Diet: Any Association with NAFLD? Antioxidants (Basel), 12, Article No. 1318. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Niederseer, D., Wernly, B., Aigner, E., et al. (2021) NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. Journal of Clinical Medicine, 10, Article No. 467. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Ormazabal, V., Nair, S., Elfeky, O., et al. (2018) Association between Insulin Resistance and the Development of Cardiovascular Disease. Cardiovascular Diabetology, 17, Article No. 122. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Khan, R.S., Bril, F., Cusi, K., et al. (2019) Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology, 70, 711-724. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Jia, G., DeMarco, V.G. and Sowers, J.R. (2016) Insulin Resistance and Hyperinsulinaemia in Diabetic Cardiomyopathy. Nature Reviews: Endocrinology, 12, 144-153. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Siddiqui, M.S., Fuchs, M., Idowu, M.O., et al. (2015) Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated with Atherogenic Lipoprotein Profile. Clinical Gastroenterology and Hepatology, 13, 1000-1008.E1003. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Zelber-Sagi, S., Salomone, F., Yeshua, H., et al. (2014) Non-High-Density Lipoprotein Cholesterol Independently Predicts New Onset of Non-Alcoholic Fatty Liver Disease. Liver International, 34, E128-E135. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Wegermann, K., Fudim, M., Henao, R., et al. (2023) Serum Metabolites Are Associated with HFpEF in Biopsy-Proven Nonalcoholic Fatty Liver Disease. Journal of the American Heart Association, 12, E029873. [Google Scholar] [CrossRef]
|
|
[43]
|
O'Rourke, R.W., Metcalf, M.D., White, A.E., et al. (2009) Depot-Specific Differences in Inflammatory Mediators and a Role for NK Cells and IFN-Gamma in Inflammation in Human Adipose Tissue. International Journal of Obesity (2005), 33, 978-990. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Tilg, H. and Moschen, A.R. (2006) Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. Nature Reviews: Immunology, 6, 772-783. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Polyzos, S.A., Aronis, K.N., Kountouras, J., et al. (2016) Circulating Leptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Diabetologia, 59, 30-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Chait, A. and Den Hartigh, L.J. (2020) Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 7, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Tilg, H., Adolph, T.E. and Moschen, A.R. (2021) Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited after a Decade. Hepatology, 73, 833-842. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Matthew Morris, E., Fletcher, J.A., Thyfault, J.P., et al. (2013) The Role of Angiotensin II in Nonalcoholic Steatohepatitis. Molecular and Cellular Endocrinology, 378, 29-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Min, L.J., Mogi, M., Iwai, M., et al. (2009) Signaling Mechanisms of Angiotensin II in Regulating Vascular Senescence. Ageing Research Reviews, 8, 113-121. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Patel, V.B., Zhong, J.C., Grant, M.B., et al. (2016) Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circulation Research, 118, 1313-1326. [Google Scholar] [CrossRef]
|
|
[51]
|
Levick, S.P., Murray, D.B., Janicki, J.S., et al. (2010) Sympathetic Nervous System Modulation of Inflammation and Remodeling in the Hypertensive Heart. Hypertension, 55, 270-276. [Google Scholar] [CrossRef]
|
|
[52]
|
Targher, G., Mantovani, A., Grander, C., et al. (2021) Association between Non-Alcoholic Fatty Liver Disease and Impaired Cardiac Sympathetic/Parasympathetic Balance in Subjects with and without Type 2 Diabetes—The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD Sub-Study. Nutrition, Metabolism, and Cardiovascular Diseases, 31, 3464-3473. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Ingelsson, E., Bennet, L., Ridderstråle, M., et al. (2008) The PPARGC1A Gly482Ser Polymorphism Is Associated with Left Ventricular Diastolic Dysfunction in Men. BMC Cardiovascular Disorders, 8, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Liu, J., Xiao, Y., Wu, X., et al. (2018) A Circulating MicroRNA Signature as Noninvasive Diagnostic and Prognostic Biomarkers for Nonalcoholic Steatohepatitis. BMC Genomics, 19, Article No. 188. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Climent, M., Viggiani, G., Chen, Y.W., et al. (2020) MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases. International Journal of Molecular Sciences, 21, Article No. 4370. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Li, X.L., Sui, J.Q., Lu, L.L., et al. (2016) Gene Polymorphisms Associated with Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: A Concise Review. Lipids in Health and Disease, 15, Article No. 53. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Ren, Z., Simons, P., Wesselius, A., et al. (2023) Relationship between NAFLD and Coronary Artery Disease: A Mendelian Randomization Study. Hepatology, 77, 230-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Peng, H., Wang, S., Wang, M., et al. (2022) Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: A Mendelian Randomization Study. Metabolism: Clinical and Experimental, 133, Article ID: 155220. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Effenberger, M., Grander, C., Grabherr, F., et al. (2023) Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link. Journal of Clinical and Translational Hepatology, 11, 1498-1507. [Google Scholar] [CrossRef]
|
|
[60]
|
Albillos, A., De Gottardi, A. and Rescigno, M. (2020) The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy. Journal of Hepatology, 72, 558-577. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Hu, H., Lin, A., Kong, M., et al. (2020) Intestinal Microbiome and NAFLD: Molecular Insights and Therapeutic Perspectives. Journal of Gastroenterology, 55, 142-158. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Yang, W., Zhang, S., Zhu, J., et al. (2019) Gut Microbe-Derived Metabolite Trimethylamine N-Oxide Accelerates Fibroblast-Myofibroblast Differentiation and Induces Cardiac Fibrosis. Journal of Molecular and Cellular Cardiology, 134, 119-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Witkowski, M., Weeks, T.L. and Hazen, S.L. (2020) Gut Microbiota and Cardiovascular Disease. Circulation Research, 127, 553-570. [Google Scholar] [CrossRef]
|
|
[64]
|
Loomba, R., Seguritan, V., Li, W., et al. (2017) Gut Microbiome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism, 25, 1054-1062.E1055. [Google Scholar] [CrossRef] [PubMed]
|